Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Pfizer’s announced purchase of Arena Pharmaceuticals exemplifies a satisfactory acquisition within the CBD medical treatment industry

CS MEDICA A/S (”CS MEDICA” or the ”Company”) see a strategic turnaround and new era for the CBD Medical treatment sector as Pfizer has announced the acquisition of Arena Pharmaceuticals. The acquisition exemplifies Big Pharma moving into the Cannabinoid treatment space and acknowledging Cannabinoids (CBD) in the medical treatment market.Pfizer’s announced[1] purchase of the US clinical-trial stage cannabinoids company, Arena Pharmaceuticals, exemplifies a satisfactory acquisition and a game-changer for CS MEDICA and the CBD medical treatment industry in which the Company operates. With this

CS MEDICA A/S: Statement of Extraordinary General Meeting

Today on February 3, 2022, in Copenhagen - CS MEDICA A/S (”CS MEDICA” or the ”Company”) held an extraordinary general meeting (“EGM”) at which the following principal resolutions were passed.Resolution concerning proposal to issue up to 798,000 incentive/bonus warrants to newly hired sales employeesThe EGM resolved in accordance with the Board of Directors’ proposal, to approve the issue of up to 798,000 incentive/bonus warrants to newly hired sales employees. Resolution concerning proposal to issue incentive warrants to Diaz Capital Invest ABThe EGM resolved in accordance with the

CS MEDICA A/S signs partnership with Ampilio in preparation of Amazon expansion

CS MEDICA A/S (“CS MEDICA” or the “Company”) announces today that the Company has signed a partnership with Ampilio AB (“Ampilio”), a subsidiary of SpectrumOne. Ampilio will assist CS MEDICA as a business strategist, growth specialist as CS MEDICA prepares to execute global expansion on Amazon. The agreement comprises that Ampilio will run sales activities and develop a digital strategy and assist CS MEDICA in the global launch on Amazon. The partnership is a running agreement with a fixed annual fee of 270 000 SEK.CS MEDICA is currently working on expanding the Company’s marketing

Ampilio, a subsidiary of SpectrumOne, signs with Danish company CS MEDICA A/S to execute on expansion

Ampilio, a subsidiary of SpectrumOne, partners up with stock exchange listed medical company CS MEDICA as digital business strategist, growth specialists and executor of their  global expansion on Amazon. Ampilio will run all sales, digital strategy, and expansion on Amazon with a global launch. The deal is valued at 270 000 SEK annually with a continued agreement until either partner decides otherwise.  CS MEDICA is a Danish leading OTC Medical Device Provider active in medical technology. The company specializes in the development of medical devices. The portfolio includes products

CS MEDICA A/S: Updated Notice of Extraordinary General Meeting

The update: The updated proposals are under item 3 in the agenda and are (i) that 100,000 (out of the 600,000) warrants vest immediately upon grant and (ii) changes to the exercise periods for the TO2 and TO3 Warrants.“On 20 January 2022 CS MEDICA A/S ("CS MEDICA" or the "Company") sent out a press release to convene an extraordinary general meeting to be held 3 February 2022 at 17:00. The press release lacked more detailed information about (i) the nature of the warrants which the board of directors proposes that the Company shall issue, and (ii) a more detailed presentation of the

CS MEDICA A/S: Chairman of the Board buys shares in CS MEDICA

CS MEDICA A/S ("CS MEDICA" or the "Company") announces today that the Chairman of the Board, Jørgen Flemming Ladefoged, has purchased 22,000 stocks in the Company.Chairman of the Board of Directors of CS MEDICA, Jørgen Flemming Ladefoged, has purchased 22,000 shares in the open market at a price of DKK 7,05 per share, corresponding to a total purchase of 155,100 DKK. The transaction has been disclosed in the Danish financial supervisory register. Following the transaction, Jørgen Flemming Ladefoged owns 22,000 CS MEDICA shares.

Correction: CS MEDICA A/S: Notice of Extraordinary General Meeting

“On 20 January 2022 CS MEDICA A/S ("CS MEDICA" or the "Company") sent out a press release to convene an extraordinary general meeting to be held 3 February 2022 at 17:00. The press release lacked more detailed information about (i) the nature of the warrants which the board of directors proposes that the Company shall issue, and (ii) a more detailed presentation of the proposed new board member.  Consequently, this press release is sent out to correct the press release sent out 20 January 2022. Finally, the press release sent out 20 January 2022 was wrongly marked under the Swedish Securities

CS MEDICA A/S: Notice of Extraordinary General Meeting

The shareholders of CS MEDICA A/S ("CS MEDICA" or the "Company") are hereby notified of an Extraordinary General Meeting that will be held on Tuesday February 3, 2022 at 17:00 at TEAMS. Shareholders will be entitled to vote by submitting postal vote forms prior to the meeting. Information about the resolutions passed at the meeting will be made public February 3, 2022 after the extraordinary general meeting has been held.RegistrationThe registration date is 27 January 2022. Only those who are shareholders on this date have the right to participate and vote at the extraordinary general

CS MEDICA recruits 4 new employees to strengthen the sales department

CS MEDICA A/S (“CS MEDICA” or the “Company”) announces today that the Company has hired four persons to strengthen the sales department. Until now, the Company has mainly been characterized as an early-staged R&D-centric development company. CS MEDICA will now focus on improving enterprise sales and establishing an enterprise-ready sales organization to grow further and penetrate new markets.With the intention to become more sales-focused, CS MEDICA has strengthened the team by hiring an additional four persons. The Company is currently in the process of transforming from mainly being an R&

CS MEDICA A/S sees great value in Germany’s proposed legislation of cannabis

CS MEDICA A/S (”CS MEDICA” or the ”Company”) sees great potential in the German market following the proposal from the new German coalition government regarding the establishment of a regulated market that allows controlled sales of cannabis for adults for recreational purposes and in doing so, promotes a broader drug policy.The new government led by Olaf Scholz has presented a proposal that would allow the controlled sale of cannabis to adults for recreational purposes in licensed shops. In more detail, the proposal includes the establishment of a regulated market for sale to adults, the

CS MEDICA A/S: Update on IPR rights

CS MEDICA A/S (”CS MEDICA” or the ”Company”) announces that an additional five Intellectual Property Rights (IPR) registrations have been made for CANNASEN, and the Company hereby provides an update on the Company’s IPR and trademark.CS MEDICA’s product line, CANNASEN® CBD is the world’s first over-the-counter medical technical treatment products with cannabinoids. Intellectual Property Rights (IPR) is a key element for CS MEDICA to ensure economic growth and is continually extended when entering new markets. CS MEDICA can now confirm that the Company has officially completed an

CS MEDICA A/S: Notice of Shareholders Annual Meeting

Today on December 9, 2021, in Copenhagen - CS MEDICA A/S (”CS MEDICA” or the ”Company”) held its annual general meeting (“AGM”) at which the following principal resolutions were passed.Presentation of the annual report with auditors’ report for adoptionThe AGM resolved in accordance with the Board of Directors’ proposal, to approve the annual report presented during the AGM. Resolution concerning the appropriation of profits or losses as recorded in the adopted annual reportThe AGM resolved, in accordance with the Board of Directors’ proposal, that the result for the period 1 October

CS MEDICA A/S: Danish Parliament voted yes for a permanent scheme for medical cannabis in Denmark

CS MEDICA A/S (”CS MEDICA” or the ”Company”) hereby announces that the Danish Parliament has voted unanimously, to make the current Pilot Programme for medical cannabis a permanent scheme. Companies’ opportunities to produce medical cannabis become permanent, while doctors' ability to prescribe cannabis drugs is extended by four years.The Danish Parliament voted unanimously, 102-0, to make the current pilot program for medical cannabis a permanent scheme. In doing so, companies will be able to manufacture cannabis for medical use on a permanent basis. In addition, doctors are now able to

CS MEDICA - Updates regarding market territory

CS MEDICA A/S (”CS MEDICA” or the ”Company”) hereby announces that the Company has obtained Free Sales Certificate (FSC) from the Danish Medicines Agency and The Danish Chamber of Commerce for medical devices and cosmetics products respectively. The FSC is valid until November 2023 and allows CS MEDICA to sell and distribute products to countries outside of the EU.CS MEDICA is working under the Medical Devices Directive (MDD) legislation and is in process of updating according to the new MDR regulation monitored by the Danish Medicines Agency.  The area covered by this authority includes

CS MEDICA A/S: Notice of Shareholders Annual Meeting

The shareholders of CS MEDICA A/S (”CS MEDICA” or the ”Company”) are hereby notified of the Annual General Meeting that will be held on Thursday December 9, 2021 at 15:00 at the offices of the Company, Fruebjergvej 3, 2100 Copenhagen, Denmark. Shareholder will be entitled to vote by submitting postal vote forms prior to the meeting. Information about the resolutions passed at the meeting will be made public December 9, 2021 after the general meeting has been held.RegistrationThe registration date is 2 December 2021. Only those who are shareholders on this date have the right to

Correction: CS MEDICA A/S: Publication of year-end report

“Correction: The year-end report for the period October 2020 – September 2021 lacked information on whether the interim report was subject to review by the company's auditor. The year-end report has not been subject to review by the company's auditor. Revised year-end report is available on CS MEDICA's website and as an attachment.”Performance highlights   · Operating profit for the year increased by 165% in Danish kroner and in the fourth quarter with 1.130% compared to 2019/2020.  · Net Sales for the year increased by 51% in Danish kroner compared

CS MEDICA A/S: Publication of Year-end report

CS MEDICA A/S (”CS MEDICA” or the ”Company”) hereby publishes its year-end report for the period October 2020 –September 2021. The report is available as an attached document to this press release and on the Company’s website (www.cs-medica.com). Below is a summary of the report.Performance highlights   · Operating profit for the year increased by 165% in Danish kroner and in the fourth quarter with 1.130% compared to 2019/2020.  · Net Sales for the year increased by 51% in Danish kroner compared to 2019/2020. Net Sales in the fourth quarter increased by 682% in Danish kroner

Cannordic enters a reseller agreement for Cannasen®CBD product portfolio with DirectSalud in Spain.

CS MEDICA A/S (”CS MEDICA” or the ”Company”) hereby announces that the Company’s subsidiary CanNordic has entered into a reseller agreement with the DirectSalud (“DirectSalud”)Today, November 5, CS MEDICA announces that the Company has entered into a reseller agreement with DirectSalud. a Spanish and leading international business partnering with worldwide customers. The reseller agreementThe reseller agreement is non-exclusive and runs initially for 12 months commencing today, October 5 2021, and can be renewed every 12 months. The agreement can be terminated by either party with a 2

CS MEDICA announce extended product availability together with Kronan Apotek in Sweden

CS MEDICA A/S (”CS MEDICA” or the ”Company”) announces today, October 4, that the Company’s purchase agreement together with Kronan Droghandel Apotek AB (“Kronans Apotek”) will now also include product sales of their Cannasen® CBD product line in 326 local pharmacies in Sweden.CS MEDICA is a Danish medico cannabis company that envisions playing a central role in ensuring the best treatments within healthcare and wellness for patients, healthcare professionals, and consumers around the world. The Company fulfills this purpose by introducing and providing the most effective and innovative OTC

Update on operations and financial targets for the fiscal year 2020/2021

CS MEDICA A/S’s (”CS MEDICA” or the ”Company”) will adjust its financial targets for the fiscal year 2020/2021. The previously communicated financial target of DKK 7 million will be adjusted to approx. DKK 3.6 million. The completion of the process of testing and getting approval by the ethics committee in India was prolonged due to Covid-19, in turn impacting and postponing the finalization of an agreement. The Company is experiencing great interest in the product portfolio and sees no reason to revise future objectives, rather, the Company expects that ongoing in-depth dialogues and already

First day of trading in CS MEDICA

Today is the first day of trading on the Spotlight Stock Market in Denmark for CS MEDICA, a Danish company active in the development of medical devices. Their portfolio includes products that contain medical cannabis (CBD), with the greatest focus on dietary supplements and various treatment care.CS MEDICA is a Danish company active in medical technology. The company specializes in the development of medical devices. The portfolio includes products that contain medical cannabis (CBD). The products are used, for example, by patients suffering from psoriasis, arthritis, and hair loss. The

CS MEDICA signs agreement on arthritis gel with Alsitan in Germany

CS MEDICA A/S’s (”CS MEDICA” or the ”Company”) announces today that the Company has signed an agreement with Alsitan GmbH (“Alsitan”) in Germany, in line with previously communicated confirmed orders. The order, which concerns arthritis gel under a private label agreement, amounts to 40,000 units, corresponding to DKK 1.240.000 million in revenue. The order is expected to be delivered in September and December 2021.Lone Henriksen comments“As this is our first order by a private label customer, we are very excited. This agreement signifies the potential for further advances in the private

First day of trading in CS MEDICA’s shares and warrants at Spotlight Stock Market

Today is the first day of trading in CS MEDICA A/S’s (”CS MEDICA” or the ”Company”)  shares and warrants. CS MEDICA’s shares are traded under the ticker “CSMED” with ISIN DK0061668225 and the Company’s warrants are traded under the ticker “CSMED TO 1” with ISIN DK0061668308.Prior to listing at Spotlight Stock Market, CS MEDICA conducted a successful IPO which was subscribed to a total of approx. 158 percent. The capitalization provided the Company with initially approx. DKK 22.3 million (before issue costs, offset of bridge loan financing and compensation). The number of shares in the

There are no items matching the current filter
There are no more items matching the current filter
Back to top